Brazil’s federal health regulator Anvisa signed off on clinical trials for a new potential coronavirus vaccine, developed by pharmaceutical companies Medicago, from Canada, and GlaxoSmithKline (GSK), from the United Kingdom.
The vaccine will be administered in two shots, over a period of 21 days. Anvisa claims phase 1 and 2 trial data “presented a safety profile acceptable for potential vaccines.”
Phase 3 trials will include up to 30,000 volunteers in Canada, the U.S., Latin America, and Europe.
Search
